Mitsubishi
Navigation Links
Mitsubishi in Medical News
WATERTOWN, Mass., April 1, /PRNewswire/ -- EnVivo Pharmaceuticals today announced an agreement with Mitsubishi Tanabe Pharma Corporation (MTPC) for the development and commercialization of its lead product candidate, EVP-6124, in Japan and several other Asian countries.
EVP-6124 is EnVivo's ...
...or use as a systemic drug in the treatment of allergic rhinitis and urticaria/pruritus in July 2000 and January 2002, respectively, and is marketed by mitsubishi Tanabe Pharma Corporation (formerly Tanabe Seiyaku Co., Ltd.) under the brand name TALION(R). TALION was co-developed by Tanabe Seiyaku and Ube Indus...
...Expiration Date. Quest Diagnostics has retained Banc of America Securities LLC to act as Lead Dealer Manager and Calyon Securities (USA) Inc. and mitsubishi UFJ Securities (USA), Inc. to serve as Co-Dealer Managers. Global Bondholder Services Corporation has been retained to serve as the depositary and as...
...xpiration Date. Quest Diagnostics has retained Banc of America Securities LLC to act as Lead Dealer Manager and Calyon Securities (USA) Inc. and mitsubishi UFJ Securities (USA), Inc. to serve as Co-Dealer Managers. Global Bondholder Services Corporation has been retained to serve as the depositary and th...
...or use as a systemic drug in the treatment of allergic rhinitis and urticaria/pruritus in July 2000 and January 2002, respectively, and is marketed by mitsubishi Tanabe Pharma Corporation (formerly Tanabe Seiyaku Co., Ltd.) under the brand name TALION(R). TALION was co-developed by Tanabe Seiyaku and Ube Indus...
...Expiration Date. Quest Diagnostics has retained Banc of America Securities LLC to act as Lead Dealer Manager and Calyon Securities (USA) Inc. and mitsubishi UFJ Securities (USA), Inc. to serve as Co-Dealer Managers. Global Bondholder Services Corporation has been retained to serve as the depositary and to ...
Medarex Announces Collaborative Research Agreement With Mitsubishi Pharma
Medarex, Inc. today announced a collaborative research agreement with Mitsubishi Pharma Corporation, a subsidiary of Mitsubishi Chemical Holdings Corporation . The two companies expect to generate and evaluate fully human monoclonal antibodies against a Mitsubishi target for the potential treatment...BioMed Realty Trust Commemorates Five-Year Anniversary as a Public Company
..., in addition to potential milestone payments, from the sale of commercialization rights of telaprevir in Japan and other countries in the Far East to mitsubishi Tanabe Pharma Corporation, after announcing its intention to sell certain future European milestone payments for telaprevir aggregating $250 million e......or use as a systemic drug in the treatment of allergic rhinitis and urticaria/pruritus in July 2000 and January 2002, respectively, and is marketed by mitsubishi Tanabe Pharma Corporation (formerly Tanabe Seiyaku Co., Ltd.) under the brand name TALION(R). TALION was co-developed by Tanabe Seiyaku and Ube Indus...
PATHFAST(R) Rapid Whole Blood Immunoassay Analyzer from Polymedco
...unce the introduction of the PATHFAST immunoassay analyzer, manufactured by mitsubishi Chemical Medience Corporation, Tokyo, Japan. The PATHFAST rapid point of c...and diagnostic kits to the medical market. PATHFAST is a registered mark of mitsubishi Chemical Medience Corporation, Tokyo, Japan. For more information, ple......Expiration Date. Quest Diagnostics has retained Banc of America Securities LLC to act as Lead Dealer Manager and Calyon Securities (USA) Inc. and mitsubishi UFJ Securities (USA), Inc. to serve as Co-Dealer Managers. Global Bondholder Services Corporation has been retained to serve as the depositary and as...
...xpiration Date. Quest Diagnostics has retained Banc of America Securities LLC to act as Lead Dealer Manager and Calyon Securities (USA) Inc. and mitsubishi UFJ Securities (USA), Inc. to serve as Co-Dealer Managers. Global Bondholder Services Corporation has been retained to serve as the depositary and th...
...or use as a systemic drug in the treatment of allergic rhinitis and urticaria/pruritus in July 2000 and January 2002, respectively, and is marketed by mitsubishi Tanabe Pharma Corporation (formerly Tanabe Seiyaku Co., Ltd.) under the brand name TALION(R). TALION was co-developed by Tanabe Seiyaku and Ube Indus...
ProCure Treatment Centers to Equip Chicago Facility With Software Solutions From Elekta
...ns is in clinical use at more proton facilities than any other commercial vendor. Vendor-neutral, XiO also is used in conjunction with IBA, Varian and mitsubishi delivery systems. "Because of their proven track record, ease of use and commitment to future enhancements, ProCure selected the Elekta systems f......Expiration Date. Quest Diagnostics has retained Banc of America Securities LLC to act as Lead Dealer Manager and Calyon Securities (USA) Inc. and mitsubishi UFJ Securities (USA), Inc. to serve as Co-Dealer Managers. Global Bondholder Services Corporation has been retained to serve as the depositary and to ...
Mitsubishi in Medical Technology
...-Plough will assume exclusive marketing rights outside the United States except in Japan, Indonesia and Taiwan, where golimumab will be co-marketed by mitsubishi Tanabe Pharma Corporation and Janssen Pharmaceutical Kabushiki Kaisha; Hong Kong, where golimumab will be exclusively marketed by Janssen-Cilag; and C...
...-Plough will assume exclusive marketing rights outside the United States except in Japan, Indonesia and Taiwan, where SIMPONI will be co-marketed by mitsubishi Tanabe Pharma Corporation and Janssen Pharmaceutical Kabushiki Kaisha; Hong Kong, where SIMPONI will be exclusively marketed by Janssen-Cilag; and Chi...
...ng-Plough will assume exclusive marketing rights outside the United States except in Japan, Indonesia and Taiwan, where SIMPONI will be co-marketed by mitsubishi Tanabe Pharma Corporation and Janssen Pharmaceutical Kabushiki Kaisha; Hong Kong, where SIMPONI will be exclusively marketed by Janssen-Cilag; and Chi...
...or use as a systemic drug in the treatment of allergic rhinitis and urticaria/pruritus in July 2000 and January 2002, respectively, and is marketed by mitsubishi Tanabe Pharma Corporation (formerly Tanabe Seiyaku Co., Ltd.) under the brand name TALION(R). TALION was co-developed by Tanabe Seiyaku and Ube Indus...
...inical targets are schizophrenia, anxiety and chronic pain. Complementing its own preclinical excellence R&D collaboration agreements were signed with mitsubishi Pharma Corporation (Japan) and Forest Laboratories in 2004 and 2005. The company has an original R&D portfolio with 17 ongoing projects including four...
... Schering-Plough has exclusive marketing rights outside the United States except in Japan, Indonesia and Taiwan where golimumab will be co-marketed by mitsubishi Tanabe Pharma Corporation and Janssen Pharmaceutical Kabushiki Kaisha; Hong Kong, where golimumab will be exclusively marketed by Janssen-Cilag; and C...
... Schering-Plough has exclusive marketing rights outside the United States except in Japan, Indonesia and Taiwan where golimumab will be co-marketed by mitsubishi Tanabe Pharma Corporation and Janssen Pharmaceutical Kabushiki Kaisha; Hong Kong, where golimumab will be exclusively marketed by Janssen-Cilag; and C...
...inical targets are schizophrenia, anxiety and chronic pain. Complementing its own preclinical excellence R&D collaboration agreements were signed with mitsubishi Pharma Corporation (Japan) and Forest Laboratories in 2004 and 2005. The company has an original R&D portfolio with 16 ongoing projects including four...
...-Plough will assume exclusive marketing rights outside the United States except in Japan, Indonesia and Taiwan, where SIMPONI will be co-marketed by mitsubishi Tanabe Pharma Corporation and Janssen Pharmaceutical Kabushiki Kaisha; Hong Kong, where SIMPONI will be exclusively marketed by Janssen-Cilag; and Chi...
...ng-Plough will assume exclusive marketing rights outside the United States except in Japan, Indonesia and Taiwan, where SIMPONI will be co-marketed by mitsubishi Tanabe Pharma Corporation and Janssen Pharmaceutical Kabushiki Kaisha; Hong Kong, where SIMPONI will be exclusively marketed by Janssen-Cilag; and Chi...
ISTA Pharmaceuticals Announces Positive Results for Phase IIb Study of Ecabet Sodium
...Senju Pharmaceuticals Co., Ltd., in November of 2004. Ecabet sodium is already marketed in Japan as an oral agent for gastric ulcers and gastritis by mitsubishi Tanabe Pharma Corporation (formerly Tanabe Seiyaku Co., Ltd.) as an originator of ecabet sodium. Ecabet sodium represents a new class of molecule......or use as a systemic drug in the treatment of allergic rhinitis and urticaria/pruritus in July 2000 and January 2002, respectively, and is marketed by mitsubishi Tanabe Pharma Corporation (formerly Tanabe Seiyaku Co., Ltd.) under the brand name TALION(R). TALION was co-developed by Tanabe Seiyaku and Ube Indus...
...inical targets are schizophrenia, anxiety and chronic pain. Complementing its own preclinical excellence R&D collaboration agreements were signed with mitsubishi Pharma Corporation (Japan) and Forest Laboratories in 2004 and 2005. The company has an original R&D portfolio with 17 ongoing projects including four...
ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing
...or use as a systemic drug in the treatment of allergic rhinitis and urticaria/pruritus in July 2000 and January 2002, respectively, and is marketed by mitsubishi Tanabe Pharma Corporation (formerly Tanabe Seiyaku Co., Ltd.) under the brand name TALION(R). TALION was co-developed by Tanabe Seiyaku and Ube Indust...... Schering-Plough has exclusive marketing rights outside the United States except in Japan, Indonesia and Taiwan where golimumab will be co-marketed by mitsubishi Tanabe Pharma Corporation and Janssen Pharmaceutical Kabushiki Kaisha; Hong Kong, where golimumab will be exclusively marketed by Janssen-Cilag; and C...
... Schering-Plough has exclusive marketing rights outside the United States except in Japan, Indonesia and Taiwan where golimumab will be co-marketed by mitsubishi Tanabe Pharma Corporation and Janssen Pharmaceutical Kabushiki Kaisha; Hong Kong, where golimumab will be exclusively marketed by Janssen-Cilag; and C...
...inical targets are schizophrenia, anxiety and chronic pain. Complementing its own preclinical excellence R&D collaboration agreements were signed with mitsubishi Pharma Corporation (Japan) and Forest Laboratories in 2004 and 2005. The company has an original R&D portfolio with 16 ongoing projects including four...
Mitsubishi in Biological News
...troleum from southern Patagonia to Buenos Aires, coupled with expanding offshore oil drilling, have also loomed as growing threats in recent years.
mitsubishi Corporation Foundation for the Americas has provided funding for the creation of this unique coastal protected area and for WCS's multi-faceted effort...
Urea tanks on diesel trucks -- that's the law in the United States starting in 2010
...0 centers in mid to late 2009 in a Sept. 29 news release. The Pilot Centers will also carry prepackaged DEF. Aqueous Urea Production Meanwhile, mitsubishi is increasing production of high-grade aqueous urea solution for urea SCR systems, according to GreenCarCongress.com. The company's plant at Kitakyush...World's largest investor coalition seeks further disclosure on climate change and shareholder value
...tabase in the world on corporate climate change information. Investors that have signed up to CDP include Merrill Lynch, AXA, ANZ, Banco do Brazil, mitsubishi UFJ, AIG Investments, Barclays, RBS Group and HSBC. Legg Mason, Insurance Australia Group and the Florida State Board of Administration are among over...Mitsubishi in Biological Technology
SAN RAMON, Calif., May 15 /PRNewswire/ -- Odyssey Thera, Inc. announced today the initiation of a collaboration with leading Japanese pharmaceutical company Mitsubishi Tanabe Pharma Corporation. The alliance involves the analysis of drug candidates from a number of Mitsubishi Tanabe preclinical p...
MARKHAM, ON, and OSAKA, Japan, July 30 /PRNewswire/ - Cytochroma and Mitsubishi Tanabe Pharma Corporation ("MTPC") today announced that the companies have signed a license agreement under which Cytochroma granted MTPC an exclusive license in the U.S. and Asia, including Japan, to develop and c...
...ng-Plough will assume exclusive marketing rights outside the United States except in Japan, Indonesia and Taiwan, where SIMPONI will be co-marketed by mitsubishi Tanabe Pharma Corporation and Janssen Pharmaceutical Kabushiki Kaisha; Hong Kong, where SIMPONI will be exclusively marketed by Janssen-Cilag; and Chi...
...th both Big Pharma and Biotech experience in the development and commercialization of oncology therapeutics. Its investors include: Domain Associates, mitsubishi International Corporation, Morganthaler Ventures, Oxford BioScience Partners and ProQuest Investments. More information about Tragara can be found at ...
... Schering-Plough has exclusive marketing rights outside the United States except in Japan, Indonesia and Taiwan where golimumab will be co-marketed by mitsubishi Tanabe Pharma Corporation and Janssen Pharmaceutical Kabushiki Kaisha; Hong Kong, where golimumab will be exclusively marketed by Janssen-Cilag; and C...
MARKHAM, ON, and OSAKA, Japan, July 30 /PRNewswire/ - Cytochroma and Mitsubishi Tanabe Pharma Corporation ("MTPC") today announced that the companies have signed a license agreement under which Cytochroma granted MTPC an exclusive license in the U.S. and Asia, including Japan, to develop and c...
Quest Diagnostics Announces Final Tender Offer Results
...n June 18, 2009. Quest Diagnostics has retained Banc of America Securities LLC to act as Lead Dealer Manager and Calyon Securities (USA) Inc. and mitsubishi UFJ Securities (USA), Inc. to serve as Co-Dealer Managers. Global Bondholder Services Corporation has been retained to serve as the depositary and as......ng-Plough will assume exclusive marketing rights outside the United States except in Japan, Indonesia and Taiwan, where SIMPONI will be co-marketed by mitsubishi Tanabe Pharma Corporation and Janssen Pharmaceutical Kabushiki Kaisha; Hong Kong, where SIMPONI will be exclusively marketed by Janssen-Cilag; and Chi...
...th both Big Pharma and Biotech experience in the development and commercialization of oncology therapeutics. Its investors include: Domain Associates, mitsubishi International Corporation, Morganthaler Ventures, Oxford BioScience Partners and ProQuest Investments. More information about Tragara can be found at ...
BrainCells Inc. Appoints David E. Thompson to Its Board of Directors
...al stem cells, unlike an SSRI which acts by an indirect mechanism, which may eliminate serotonin associated side effects. BCI-540 was in-licensed from mitsubishi Pharma (MPC) based on its neurogenic properties and in previous studies was shown to be well tolerated in more than 900 subjects in Phase I and II cli...ISTA Pharmaceuticals Files New Drug Application with U.S. FDA for Bepreve(TM)
...or use as a systemic drug in the treatment of allergic rhinitis and urticaria/pruritus in July 2000 and January 2002, respectively, and is marketed by mitsubishi Tanabe Pharma Corporation (formerly Tanabe Seiyaku Co., Ltd.) under the brand name TALION(R). TALION was co-developed by Tanabe Seiyaku and Ube Indust...Yale professor T.P. Ma awarded the Connecticut Medal of Technology
...s companies worldwide, including IBM, Intel, Motorola, Lucent Technology, GE, Hughes, Rockwell Semiconductors, Philips, Siemens, Hitachi, Toshiba, and mitsubishi Electric. Ma is a patent holder, co-editor of a book, and contributor to several book chapters as well as over 180 research papers. He is a member ...... Schering-Plough has exclusive marketing rights outside the United States except in Japan, Indonesia and Taiwan where golimumab will be co-marketed by mitsubishi Tanabe Pharma Corporation and Janssen Pharmaceutical Kabushiki Kaisha; Hong Kong, where golimumab will be exclusively marketed by Janssen-Cilag; and C...
MacroGenics Raises $25M in Series D-2 Financing
...nd Eli Lilly and Company. Also participating in the financing were existing investors Alexandria Real Estate, Alta Partners, CIDC, InterWest Partners, mitsubishi UFJ, OrbiMed Advisors, Red Abbey Venture Partners, RiverVest, Texas Pacific Group Ventures and Ventures West. MacroGenics expects to use the proceed...Mitsubishi in Biological Products
Analog thermal printer, Mitsubishi (115/230V) for BioDoc-It and VisiDoc-It Imaging Systems from UVP
Description: Conveniently document gels, films and membranes with a high quality thermal printer. Compact, footprint printer Supplies 256 gray scale for high resolution, archive-quality thermal film prints Process low-cost prints in seconds ...Company:UVP
Description: Conveniently document gels, films and membranes with a high quality thermal printer. Compact, footprint printer Supplies 256 gray scale for high resolution, archive-quality thermal film prints Process low-cost prints in seconds ...
Company:UVP
Other TagsCYTCYTCYTCYTCYTCYTCYTCYTDiasDiasISTAISTAISTAISTAISTAISTAISTAISTAOther Contentssyrupsyrupsyrupmaplemastitismarijuanamarijuanamarijuanamastectomymastectomymedialmedialmedialmedialmedialmastoid
LeicesterCYTEAACIAllergologyDesmoteplaseDiasEcabetISTASuboxoneCollaboratorsINGNVPM4001ProjektPicoplatin
(Date:11/27/2009)... , SAN FRANCISCO, Nov. 27 /PRNewswire-FirstCal...nounced that Blair Lambert, CFO/COO, will present ...l be held at the May Fair Hotel in London, England...T. ,, To listen to a live broadcast of The Gymb... please log on to www.gymboree.com, click on "Our ...
(Date:11/27/2009)... , NEUILLY-SUR-SEINE, France, Nov. 27 /PRNe...can professional cycling team dedicated to ethical...cling champions, announced today that it will beco...ansitions Optical as a new sponsor of the team. Tr...rer of adaptive eyewear, offering the most advance...
(Date:11/27/2009)... XenaCare Holdings has announ...rthritis Foundation, one of the largest nonprofit ...public health education. , ...naCare Holdings, Inc. (OTCBB: XCHO), a company spe... of consumer healthcare products, has announced to...
(Date:11/27/2009)...ing rates to bring unprecedented medical, economic.... 27 (HealthDay News) -- The number of people with...le over the next 25 years, a new study predicts. ,....1 million people with the disease, up from 23.7 m...treating people with diabetes will triple, the stu...
(Date:11/27/2009)... Voyant Health™ announc...gan) has licensed its TraumaCad Enterprise orthope...orkflow solution. , (PRWE...nced today that Spectrum Health (Grand Rapids, Mic...pedic templating solution and its TraumaCad Extend...
Breaking Medicine News(10 mins):Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3[0] The Gymboree Corporation to Present at NASDAQ OMX 23rd Investor Program[0] Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor[0] XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation [0] Diabetes Cases Expected to Double in 25 Years[0] Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend
(Date:11/24/2009)..., NEW YORK (November 24, 2009) -- Th...day a report revealing that the last remaining pop...nificantly due to the rising tide of poaching and ...will help inform Russian officials of what needs t...world,s biggest cat. , The report w...
(Date:11/24/2009)... What constitutes fish food is a matter of debate....at fish get almost 50 percent of their carbon from...between the terrestrial and aquatic ecosystems. ,...on shows this is not likely to be true. Algae prov...life, according to research published this week in...
(Date:11/24/2009)... This release is available in Spanish . , T...igher levels of inflammatory substances in the blo...t; as shown by a research project of the Universit..., a scientist at the School of Pharmacy. , The p...study in relation to the control of body weight an...
Breaking Biology News(10 mins):Report shows dramatic decline in Siberian tigers 2Fish food fight: Fish don't eat trees after all, says new study 2Fish food fight: Fish don't eat trees after all, says new study 3It can be predicted the reaction obese patients will have to a diet 2Maternal child health focus of African Science Academies meeting in Ghana Nov 9 11 58053 1McDonalization of frogs 10037 1McDonalization of frogs 10037 2McDonalization of frogs 10037 3McDonalization of frogs 10037 4Independence Blue Cross Wins Disease Management Association of Americas Quality Award for Greatest Impact on Satisfaction 58048 1Independence Blue Cross Wins Disease Management Association of Americas Quality Award for Greatest Impact on Satisfaction 58048 2Independence Blue Cross Wins Disease Management Association of Americas Quality Award for Greatest Impact on Satisfaction 58048 3Independence Blue Cross Wins Disease Management Association of Americas Quality Award for Greatest Impact on Satisfaction 58048 4| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |